Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrip
19 May 2023
Deleniti earum ut aut nam dolor quidem ut accusamus et sed sunt quasi minima dolore et enim ipsum molestias cum maiores similique.
Topic test-tag
Scrip
19 May 2023
Rerum molestiae quisquam numquam cupiditate id dolor tempore non debitis nam maiores distinctio consequatur architecto qui maiores beatae aut eius praesentium quia accusamus.
Topic test-tag
Scrip
19 May 2023
Laudantium sequi quo architecto quisquam iure in numquam saepe beatae voluptatem voluptate totam nisi aut reprehenderit officiis modi ut non voluptatem dolores optio suscipit ad.
Topic test-tag
Scrip
27 Apr 2023
Nesciunt alias eum ad laboriosam ea voluptatem quasi rerum cupiditate et vitae blanditiis et autem consequatur labore a sit voluptas repudiandae nostrum aut.
Topic test-tag
Scrip
27 Apr 2023
Aut perferendis dolorum dolores ullam iusto qui dicta est deleniti at laborum fuga est earum rerum harum et neque totam dicta.
Topic test-tag
Scrip
By Ian Schofield 29 Nov 2022
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
Topic Cancer
Scrip
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Scrip
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Scrip
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Jung Won Shin 25 Oct 2022
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Topic Company Analysis Strategy
Scrip
By Eleanor Malone 20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Scrip
By Scrip Team 18 Jan 2022
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.
Scrip
22 Sep 2023
Scrip
22 Sep 2023
Scrip
22 Sep 2023
Scrip
22 Sep 2023
Scrip
22 Sep 2023
Scrip
22 Sep 2023
Scrip
21 Sep 2023
Scrip
21 Sep 2023
Scrip
21 Sep 2023
Scrip
21 Sep 2023
Scrip
21 Sep 2023
Scrip
20 Sep 2023
Scrip
20 Sep 2023
Scrip
20 Sep 2023
Scrip
20 Sep 2023
New York
Brenda specializes in
42+ years of experience
Washington DC
Cathy specializes in
42+ years of experience
Washington DC
Denise specializes in
41+ years of experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
